Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$35.38 USD
-1.54 (-4.17%)
Updated May 28, 2024 04:00 PM ET
After-Market: $35.38 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 41 - 60 ( 411 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CDX-0159 Program Expands as Expected With Initiation of Phase 1b Trial in CINDU.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continuing to Build the CDX-1140 Story; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; CDX-1140 Data up Next at SITC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Engines Are Revvin''; Target Increased to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Urticaria Squarely in the Sights of CDX-0159
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; The Reset Is Complete With All Eyes on CDX-0159 and CDX-1140
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CDX-0159 Starts off on Strong Footing; The Mast Cell Should Fear Next Steps
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bolstering CDX-301 Individual Role as Combo Program Progresses
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Programs Expanding at a Steady Clip; Positive Early CDX-0159 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Pipeline Chugging Along; Target Adjusted to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Rising Tide Lifts All Boats; Novartis Helps Pave Way in CSU with Breakthrough Status
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CDX-0159 Enters Clinic as Expected as Potentially Differentaited Anti-KIT Approach
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Assets Gaining Important Visibility; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J